Filter

Refine by Access

Refine By Collections

Refine by Type

Refine by Date

—
  • Print
  • Save

Search Results

You are looking at 1 - 7 of 7 items for :

  • "certolizumab" x
Clear All

Efficacy of the biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model

Orvosi Hetilap
Volume/Issue:
Volume 152: Issue 23
DOI:
https://doi.org/10.1556/oh.2011.29138
Author: Valentin Brodszky

Vollenhoven, R. F. és mtsai: Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann. Rheum. Dis., 2009, 68 , 805

Restricted access

TNF-α blocking therapy in chronic inflammatory bowel disease

Orvosi Hetilap
Volume/Issue:
Volume 150: Issue 38
DOI:
https://doi.org/10.1556/oh.2009.28689
Author: Tamás Molnár

838 Nesbitt, A., Fossatti, G., Bergin, M. és mtsai: Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents

Restricted access

Etanercept okozta szubakut pajzsmirigygyulladás

Orvosi Hetilap
Volume/Issue:
Volume 158: Issue 39
DOI:
https://doi.org/10.1556/650.2017.30796
Authors: Zoltán Hella, László Hodinka, Piroska Turbucz and Gábor László Kovács

, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional

Restricted access

Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn’s disease. National data from Hungary

Orvosi Hetilap
Volume/Issue:
Volume 152: Issue 36
DOI:
https://doi.org/10.1556/oh.2011.29200
Authors: Lajos Sándor Kiss, Tamás Szamosi, Tamás Molnár, Pál Miheller, László Lakatos, Áron Vincze, Károly Palatka, Zsolt Bartha, Beáta Gasztonyi, Ágnes Salamon, Gábor Horváth, Gábor Tamás Tóth, Klaudia Farkas, János Banai, Zsolt Tulassay, Ferenc Nagy, Mária Szenes, Gábor Veres, Barbara Dorottya Lovász, Zsuzsanna Végh, Petra Anna Golovics, Miklós Szathmári, Mária Papp and Péter László Lakatos

829 838 Sandborn, W. J., Feagan, B. G., Stoinov, S. és mtsai: Certolizumab pegol for the treatment of Crohn’s disease. N. Engl. J. Med., 2007, 357 , 228

Open access

Targeting antigens to DEC-205 on dendritic cells induces immune protection in experimental colitis in mice

European Journal of Microbiology and Immunology
Volume/Issue:
Volume 6: Issue 1
DOI:
https://doi.org/10.1556/1886.2015.00048
Authors: Munisch Wadwa, Robert Klopfleisch, Jan Buer and Astrid M. Westendorf

. Lichtenstein GR , Thomsen OØ , Schreiber S , Lawrance IC , Hanauer SB , Hanauer SB , Bloomfield R , Sandborn WJ : Precise 3 Study Investigators: Continuous therapy with certolizumab pegol maintains remission of patients

Open access

Epidemiology, predictors and clinical aspects of loss of response to biological therapy

Orvosi Hetilap
Volume/Issue:
Volume 153: Issue 5
DOI:
https://doi.org/10.1556/oh.2012.29294
Authors: Katalin Lőrinczy, Pál Miheller, Sándor Lajos Kiss and Péter László Lakatos

., Lawrance, I. C., et al.: Maintenance therapy with certolizumab pegol for Crohn’s disease. N. Engl. J. Med., 2007, 357 , 239–250. Lawrance I. C. Maintenance therapy with certolizumab

Open access

Prediction of the disease course in inflammatory bowel diseases

Orvosi Hetilap
Volume/Issue:
Volume 151: Issue 8
DOI:
https://doi.org/10.1556/oh.2010.28813
Authors: Lajos Sándor Kiss and Péter László Lakatos

818 824 Schreiber, S., Rutgeerts, P., Fedorak, R. N. és mtsai, CDP870 Crohn’s Disease Study Group: A randomized, placebo-controlled trial of certolizumab pegol

Open access